文献速递肺结节与肺癌

AJCC第8版临床M1a非小细胞肺癌分期描述的长期生存分析

Long-Term Survival of American Joint Committee on Cancer 8th Edition Staging Descriptors for Clinical M1a Non-Small Cell Lung Cancer.
PubMed 文献 · Chest · 2023-08-05

基于美国国家癌症数据库2010-2015年25,716例cT1-4、N0-3、M1a非小细胞肺癌患者,比较恶性胸膜或心包积液、胸膜或心包结节、对侧肺结节三种M1a描述的生存差异。多因素分析显示积液型患者总生存劣于胸膜结节型(HR 0.68)和对侧结节型(HR 0.66),倾向评分匹配后积液型5年总生存为6.4%对10.6%。

要点

  • M1a积液型非小细胞肺癌总生存显著劣于胸膜结节型和对侧肺结节型。
  • 胸膜结节型与对侧肺结节型之间总生存无显著差异。
  • 倾向评分匹配后积液型5年总生存6.4%,其他M1a型10.6%。

核心结论

  • 在AJCC第8版cT1-4、N0-3、M1a非小细胞肺癌中,恶性胸膜或心包积液型肿瘤的总生存劣于胸膜结节型或对侧肺结节型肿瘤。

研究设计与样本

  • 回顾性队列研究,纳入美国国家癌症数据库2010至2015年cT1-4、N0-3、M1a非小细胞肺癌患者25,716例。
  • 采用Kaplan-Meier分析、多因素校正Cox比例风险模型和倾向评分匹配评估总生存。

主要发现

  • 25,716例中,积液型12,756例(49.6%),胸膜结节型3,589例(14.0%),对侧结节型9,371例(36.4%)。
  • 多因素校正分析中,相比积液型,胸膜结节型总生存更优(HR 0.68;95%CI 0.64-0.71;P < .001)。
  • 多因素校正分析中,相比积液型,对侧结节型总生存更优(HR 0.66;95%CI 0.64-0.69;P < .001)。
  • 胸膜结节型与对侧结节型之间总生存无显著差异。
  • 倾向评分匹配5,581对后,积液型5年总生存6.4%(95%CI 5.7-7.1),其他M1a型10.6%(95%CI 9.7-11.5),P < .001。

临床怎么用

  • 临床分期为M1a时,应区分积液型、胸膜结节型和对侧结节型,因其预后不同。
  • 积液型M1a非小细胞肺癌预后更差,可考虑更密切的随访或更积极的治疗策略。

局限性

  • 研究为基于国家癌症数据库的回顾性分析,可能存在未测量混杂。
  • 研究结果基于AJCC第8版分期,外推至其他版本需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The American Joint Committee on Cancer (AJCC) 8th edition TNM staging manual for non-small cell lung cancer (NSCLC) M1a descriptors includes tumors presenting with malignant pleural or pericardial effusion (ie, M1a-Effusion), pleural or pericardial nodule(s) (ie, M1a-Pleural), or separate tumor nodule(s) in a contralateral lobe (ie, M1a-Contralateral). RESEARCH QUESTION: Is M1a NSCLC presenting with malignant pleural or pericardial effusion associated with worse survival compared with other types of M1a NSCLC? STUDY DESIGN AND METHODS: Patients with cT1-4, N0-3, M1a NSCLC (satisfying a single M1a descriptor of M1a-Effusion, M1a-Pleural, or M1a-Contralateral), according to AJCC eighth edition staging criteria, in the National Cancer Database from 2010 to 2015 were included. Overall survival was evaluated by using Kaplan-Meier analysis, multivariable-adjusted Cox proportional hazards modeling, and propensity score matching. RESULTS: Of the 25,716 patients who met study eligibility criteria, 12,756 (49.6%) presented with M1a-Effusion tumors, 3,589 (14.0%) with M1a-Pleural tumors, and 9,371 (36.4%) with M1a-Contralateral tumors. In multivariable-adjusted analysis, compared to M1a-Effusion tumors, both M1a-Pleural tumors (hazard ratio, 0.68; 95% CI, 0.64-0.71; P < .001) and M1a-Contralateral tumors (hazard ratio, 0.66; 95% CI, 0.64-0.69; P < .001) were associated with better overall survival. No significant differences were found in overall survival between patients with M1a-Pleural tumors vs M1a-Contralateral tumors. In a propensity score-matched analysis of 5,581 patients with M1a-Effusion tumors and 5,581 patients with other M1a tumors (ie, M1a-Contralateral or M1a-Effusion), those with M1a-Effusion tumors had worse 5-year overall survival than patients with other M1a tumors (M1a-Effusion 6.4% [95% CI, 5.7-7.1] vs M1a-Other 10.6% [95% CI, 9.7-11.5]; P < .001). INTERPRETATION: In this national analysis of AJCC 8th edition cT1-4, N0-3, M1a NSCLC, tumors with malignant pleural or pericardial effusion were associated with worse overall survival than tumors with either pleural or contralateral pulmonary nodules. These findings may be taken into consideration for the upcoming ninth edition of the AJCC lung cancer staging guidelines.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Kumar A, Xu B, Srinivasan D, et al. Long-Term Survival of American Joint Committee on Cancer 8th Edition Staging Descriptors for Clinical M1a Non-Small Cell Lung Cancer. Chest. 2023. PMID: 37544427. doi:10.1016/j.chest.2023.07.4220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。